secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001558370-25-011227
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata posts Q2 2025 operating loss; announces positive AP-SA02 trial results and $15M credit from Innoviva
--------------------------------------------------------------------------------

- Q2 2025 operating loss of $6.8M vs. $11.9M loss in Q2 2024; cash at $4.3M as of June 30, 2025.
- Entered $15M secured credit agreement with Innoviva at 14% interest, matures Jan 2029; proceeds to fund AP-SA02 development.
- Positive topline results from Phase 1b/2a diSArm trial: met primary endpoints, improved clinical outcomes, no treatment-related SAEs.
- Received additional $4.65M non-dilutive funding from U.S. Department of Defense through MTEC.
- Plans end-of-Phase 2 meeting with FDA in H2 2025; expects to start Phase 3 pivotal trial in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/0001558370-25-011227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/armp-20250811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer